Filterlex Medical

What Filterlex Medical does

Filterlex Medical Ltd. is a privately held Israeli medical device company founded in 2015/2016, headquartered in Caesarea, Israel, that develops the CAPTIS® embolic protection system for use during catheter-based left-heart procedures such as Transcatheter Aortic Valve Replacement (TAVR). The CAPTIS device is a next-generation, full-body embolic protection system positioned in the aorta that uses a distinctive triple-action design—deflect, capture, and remove embolic particles—to reduce the risk of stroke, neurological deficiencies, and acute kidney injury caused by embolic debris released during TAVR. Uniquely among cerebral embolic protection devices, CAPTIS requires no additional arterial access and does not interfere with the procedure workflow, and is supported by a filed patent with CEO Sigal Eli listed as inventor.

The company operates as a single-product, pre-commercialization venture. Its primary customers are interventional cardiology departments and cardiac surgery centers that perform TAVR, and the go-to-market motion is clinical-first, with direct hospital partnerships at leading Israeli cardiac centers (Wolfson Medical Center, Rabin Medical Center) as investigational sites. The 20-patient first-in-human study completed in 2022 demonstrated 100% technical device performance success with zero cerebrovascular events, with results presented at EuroPCR 2022. Revenue mechanics are not yet active; the company has been funded to date through approximately €7M from the European Innovation Council Accelerator, a $6M Series A1, a €2.1M Horizon 2020 SME Instrument grant, a $3M private financing round, and early-stage support from Alon MedTech Ventures and Parnasa VC.

The business model is a focused capital-intensive clinical and regulatory play. The leadership team combines TAVR clinical domain expertise (CEO Sigal Eli, advisors Dr. Giora Weisz at Columbia University, Prof. Ran Kornowski at Rabin Medical Center) with veteran cardiovascular R&D and regulatory experience (CTO Eyal Teichman, VP Regulatory Vered Nitzan with prior FDA/NMPA/MDR experience at Philips), under Chairman Dr. Shimon Eckhouse, a serial Israeli medtech entrepreneur with two NASDAQ-listed exits. Distribution is planned through direct enterprise sales to tertiary and quaternary cardiac centers once regulatory approvals are secured, with no distribution partnerships currently formalized. The company won the Best Innovation Award at EuroPCR 2019 and currently operates with a 1-10 employee headcount.

Name

Filterlex Medical

Legal name

Filterlex Medical Ltd.

Website

https://filterlex.com

Company type

Private

Founded year

2016

Operating status

Operating

Headcount range

1–10 employees

Short description

Filterlex Medical is a pre-commercialization Israeli medical device company developing the CAPTIS® full-body embolic protection device designed to reduce stroke and other complications during TAVR and other catheter-based left-heart procedures performed at hospital cardiac centers.

Ownership category

akta.pro rank

Product category

Cardiovascular Medical Devices / Embolic Protection

NAICS

Surgical and Medical Instrument Manufacturing (339112)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Thrombectomy, Embolic Protection & Stroke Intervention Devices (HLAHAFAJ)

akta.pro secondary industry

Interventional Cardiology (PCI/Structural Heart) (HLAKABAB)

Keywords

• Embolic protection devices
• Structural heart devices
• TAVR embolic protection
• Cardiovascular medical devices
• Cerebral protection devices

Headquarters

HQ city

Caesarea

HQ country

Israel

HQ region

Middle East

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

1. Medical Device Sales: Filterlex generates revenue through the sale of its CAPTIS embolic protection device to hospitals and cardiac centers performing TAVR and other left-heart procedures. As a pre-commercialization medical device company that has completed first-in-human studies, full commercialization is pending regulatory approvals.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Filterlex Medical develops the CAPTIS® full-body embolic protection device, a next-generation catheter-based device designed to reduce the risk of stroke and other complications during TAVR (Transcatheter Aortic Valve Replacement) and other catheter-based left-heart procedures. The device is positioned in the aorta and uses a triple-action design that deflects, captures, and removes embolic particles, requiring no additional arterial access and integrating seamlessly with the TAVR workflow. The company is currently in pre-commercialization stage, having completed a 20-patient first-in-human study.

Product overview

Filterlex Medical is a single-product medical device company focused on developing the CAPTIS® embolic protection device. The CAPTIS is a next-generation, full-body embolic protection system designed to protect patients' brains and kidneys during left-heart catheter-based procedures like TAVR. The company operates with a focused portfolio strategy, with the CAPTIS device representing their core and only product offering.

Differentiator

Problem solved

Functional benefit

Brands

• CAPTIS: Next-generation full-body embolic protection device designed to reduce stroke risk during TAVR and other left-heart catheter-based procedures. Features a triple-action design that deflects, captures, and removes embolic particles.

Products and services

• CAPTIS® Full-Body Embolic Protection Device CAPTIS® is a next-generation full-body embolic protection device designed to reduce the risk of stroke and other complications during catheter-based structural heart procedures such as TAVR (Transcatheter Aortic Valve Replacement). It features a distinctive triple-action design (deflect, capture, remove) and is positioned in the aorta, easily and intuitively deployed and retrieved without requiring additional arterial access and without interfering with procedure workflow. It is intended for hospital interventional cardiology departments and cardiac surgery centers performing TAVR and other catheter-based left-heart procedures.

Quantifiable outcome

• 100% technical device performance success — CAPTIS was successfully deployed and retrieved in all 20 FIH study patients with no complications
• +1 more outcomes

Named customers2 records

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Two partnerships are on record, tiered core.

• Wolfson Medical CentercoreStrategic or Co-development PartnerWolfson Medical Center is a principal investigational site for the CAPTIS first-in-human study. Prof. Haim Danenberg, Head of Interventional Cardiology and principal investigator, described being thrilled with the opportunity to use the CAPTIS device to protect TAVR patients' brain and kidneys.
• Rabin Medical Center (Beilinson Hospital)coreStrategic or Co-development PartnerRabin Medical Center (Beilinson Hospital) is a principal investigational site for the CAPTIS first-in-human study. Prof. Ran Kornowski, Director of the Cardiology Center, is a co-founder, CMO, and key opinion leader who presented positive FIH results at EuroPCR 2022.

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Edwards Lifesciences: Edwards is the global TAVR market leader (SAPIEN platform) and a natural strategic acquirer of embolic protection adjacencies like CAPTIS, which would integrate into the same cath-lab procedure workflow.
• Medtronic: Medtronic's CoreValve/Evolut TAVR platform makes it a major incumbent in the structural-heart space and a comparable strategic acquirer of embolic protection technology positioned to plug into its procedural ecosystem.
• Abbott: Abbott is a broad incumbent in structural heart and vascular intervention (including its Navitor TAVR platform) and a likely strategic acquirer or commercial partner for full-body embolic protection devices like CAPTIS.

Emerging players

• Transverse Medical: Transverse Medical developed a deflector-style embolic protection device for TAVR/structural heart procedures, directly comparable in concept (aortic deflection) to CAPTIS's triple-action deflector-capture-remove design.
• Emboline: Emboline is developing the Emboliner total embolic protection catheter for use during TAVR and other left-heart procedures — a near-direct functional competitor to CAPTIS with a similar full-body protection concept.
• Silk Road Medical: Silk Road Medical commercializes the ENROUTE transcarotid stent system and embolic protection devices for carotid disease — comparable as a specialist embolic/stroke-protection medical device company with a similar clinical focus on preventing procedural stroke.
• Protembis: Protembis is developing the ProtEmbo cerebral embolic protection system for TAVR, pursuing the same clinical use case and stroke-prevention positioning as CAPTIS.

Direct peers

• Boston Scientific: Boston Scientific markets the Sentinel Cerebral Protection System, the most established embolic protection device for TAVR and CAPTIS's primary direct competitor, addressing stroke risk during the same transcatheter aortic valve procedures.
• Penumbra (Keystone Heart): Penumbra acquired Keystone Heart, whose TriGuard 3 cerebral embolic protection device competes in the same TAVR embolic protection category as CAPTIS, with a deflector-style design addressing a similar workflow.
• InspireMD: InspireMD develops the CGuard embolic protection platform for carotid and structural-heart procedures, making it a directly comparable peer in the embolic protection device category where CAPTIS operates.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/filterlex-medical-ltd-

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Funding overview

Funding rounds6 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Filterlex Medical